Company news
Futura Medical Plc (LSE:FUM) news
Futura Medical Plc news releases on 6ix. Latest, Oct 8, 2026: Board Change and Formal Sale Process Update
Press releases & updates
Board Change and Formal Sale Process Update
October 8, 2026
Positive results from further Eroxon® Intense HUT
October 7, 2026
Holding(s) in Company
October 2, 2026
Holding(s) in Company
October 1, 2026
Correction: Result of GM and Total Voting Rights
September 24, 2026
Rule 2.9 Announcement
September 9, 2026
Oversubscribed Retail Offer
September 7, 2026
Disclosure Table
September 3, 2026
Unaudited Interim Results 2026
September 1, 2026
EU Market Launch Clearance
July 31, 2026
MED3000 (Eroxon®) European Patent Opposition
July 7, 2026
Highly positive data from WSD4000 studies
June 30, 2026
New US commercial partner
June 29, 2026
Notice of AGM & availability of Annual Report
June 4, 2026
Unaudited Results for the Year Ended 31 Dec 2025
April 29, 2026
Notice of Results & Investor Presentation
April 20, 2026
Positive Eroxon® & Eroxon® “Intense” HUT results
March 23, 2026
Formal Grant of US Patent
March 18, 2026
Holding(s) in Company
March 17, 2026
Patent notice of allowance granted for the US
February 5, 2026
Trading Update
February 4, 2026
Results of WSD4000 Early Feasibility Study
January 12, 2026
Notification of major holdings
January 7, 2026
Total Voting Rights
December 31, 2025
Patent notice of allowance granted for China
December 10, 2025
Block Listing Six Monthly Return
December 9, 2025
Directors' / PDMR dealing
December 8, 2025
Board change
December 3, 2025
Result of General Meeting and Total Voting Rights
December 2, 2025
PCA Dealing
November 14, 2025
Posting of Circular and Notice of GM
November 13, 2025
Results for the six months ended 30 June 2025
September 30, 2025
Notice of Results and Investor Presentation
September 26, 2025
Trading, Business and Strategic Review Update
September 19, 2025
Board Changes, Business Update & Notice of Results
August 8, 2025
Share price movement
July 11, 2025
Board Changes
July 8, 2025
Result of AGM
June 20, 2025
Notice of AGM and availability of Annual Report
May 27, 2025
Change of Broker
April 24, 2025
Results for the Year ended 31 December 2024
April 15, 2025
Board Appointment
March 31, 2025
FY24 Trading Update and FY25 Outlook
January 30, 2025
Positive results from WSD4000 Home User study
January 15, 2025
Remuneration of Non-Executive Directors and TVR's
January 13, 2025
TR-1: Notification of major holdings
November 15, 2024
Encouraging New Product Development Pipeline
November 4, 2024
Clinical trial data presented at SMSNA
October 17, 2024
Further milestone payment triggered post US launch
October 7, 2024
Directors’ / PDMR Dealing
September 13, 2024